These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. An updated review of long-term outcomes from randomized controlled trials in approved pharmaceuticals for diabetic macular edema. Wang JK; Huang TL; Su PY; Chang PY Eye Sci; 2015 Dec; 30(4):176-83. PubMed ID: 27215008 [TBL] [Abstract][Full Text] [Related]
25. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis. Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278 [TBL] [Abstract][Full Text] [Related]
26. Characteristics and Outcomes of Full-thickness Macular Hole Repair in Patients Receiving Anti-VEGF Injections for Neovascular Age-related Macular Degeneration. Ringeisen AL; Parke DW; Dev S Int Ophthalmol Clin; 2019; 59(1):127-135. PubMed ID: 30585922 [No Abstract] [Full Text] [Related]
27. Aflibercept for inflammatory choroidal neovascularization with persistent fluid on intravitreal ranibizumab therapy. Hernández-Martínez P; Dolz-Marco R; Alonso-Plasencia M; Abreu-Gonzalez R Graefes Arch Clin Exp Ophthalmol; 2014 Aug; 252(8):1337-9. PubMed ID: 24789465 [No Abstract] [Full Text] [Related]
28. Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization. Matsuo M; Honda S; Matsumiya W; Kusuhara S; Tsukahara Y; Negi A Eur J Ophthalmol; 2012; 22(2):210-5. PubMed ID: 21534251 [TBL] [Abstract][Full Text] [Related]
29. A Prospective Masked Clinical Assessment of Inflammation After Intravitreal Injection of Ranibizumab or Aflibercept. Khanani AM; Cohen GL; Zawadzki R J Ocul Pharmacol Ther; 2016 May; 32(4):216-8. PubMed ID: 26938579 [TBL] [Abstract][Full Text] [Related]
30. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice. Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633 [TBL] [Abstract][Full Text] [Related]
31. Ranibizumab: a review of its use in myopic choroidal neovascularization. Deeks ED BioDrugs; 2014 Aug; 28(4):403-10. PubMed ID: 24972686 [TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor inhibitor use and treatment approach for choroidal neovascularization secondary to pathologic myopia. Pakzad-Vaezi K; Mehta H; Mammo Z; Tufail A Expert Opin Biol Ther; 2016 Jul; 16(7):873-81. PubMed ID: 26985834 [TBL] [Abstract][Full Text] [Related]
33. Quantitative OCT subanalysis of eyes with choroidal neovascularization switched from multiple injections of bevacizumab or ranibizumab to intravitreal aflibercept. Hariri A; Diniz B; Fou LV; Lam LA; Nittala MG; Sadda SR Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):195-200. PubMed ID: 25707044 [TBL] [Abstract][Full Text] [Related]
34. Retinal vascular changes and aqueous humor cytokines changes after aflibercept intravitreal injection in treatment-naïve myopic choroidal neovascularization. Di Antonio L; Toto L; Mastropasqua A; Brescia L; Erroi E; Lamolinara A; Di Nicola M; Mastropasqua L Sci Rep; 2018 Oct; 8(1):15631. PubMed ID: 30353107 [TBL] [Abstract][Full Text] [Related]
35. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T; Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696 [TBL] [Abstract][Full Text] [Related]
36. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124 [TBL] [Abstract][Full Text] [Related]
37. Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid. Jaffe GJ; Kaiser PK; Thompson D; Gibson A; Saroj N; Vitti R; Berliner AJ; Heier JS Ophthalmology; 2016 Sep; 123(9):1856-64. PubMed ID: 27369111 [TBL] [Abstract][Full Text] [Related]
38. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Yoon JU; Byun YJ; Koh HJ Retina; 2010 Mar; 30(3):418-24. PubMed ID: 20094012 [TBL] [Abstract][Full Text] [Related]
39. Anti-VEGF Therapy in Myopic CNV. Toto L; Di Antonio L; Costantino O; Mastropasqua R Curr Drug Targets; 2021; 22(9):1054-1063. PubMed ID: 33511955 [TBL] [Abstract][Full Text] [Related]
40. Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration. Yazdi MH; Faramarzi MA; Nikfar S; Falavarjani KG; Abdollahi M Expert Opin Biol Ther; 2015; 15(9):1349-58. PubMed ID: 26076760 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]